Entinostat (MS-275)

Name: Entinostat (MS-275)
Brand: Selleck Chemicals
SKU: S1053
Rating: 5 (294 reviews)

For research use only.

Catalog No.S1053 Synonyms: SNDX-275

294 publications

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Selleck's Entinostat (MS-275) has been cited by 294 publications

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Cell, 2019, 178(5):1115-1131

PubMed: 31442404 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Immunol, 2014, 15(5):439-48

PubMed: 24681565 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Nat Protoc, 2020, 15(3):1209-1236

PubMed: 32051612 ( click the link to review the publication )

EMBO Rep, 2020, 4;21(3):e49254

PubMed: 32009295 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

J Autoimmun, 2020, 108:102379

PubMed: 31883829 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

J Transl Med, 2020, 7;18(1):159

PubMed: 32264925 ( click the link to review the publication )

Cell Signal, 2020, 70:109573

PubMed: 32087304 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):343-356

PubMed: 31932908 ( click the link to review the publication )

PLoS One, 2020, 15;15(5):e0232985

PubMed: 32413049 ( click the link to review the publication )

Oncol Lett, 2020, 19(1):460-468

PubMed: 31897159 ( click the link to review the publication )

Pathol Res Pract, 2020, 216(4):152867

PubMed: 32067803 ( click the link to review the publication )

JCI Insight, 2020, 5(4)

PubMed: 32102981 ( click the link to review the publication )

Gastroenterology, 2019, 156(1):187-202

PubMed: 30267710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )
Nat Commun, 2019, 10(1):5324

PubMed: 31757943 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz1136

PubMed: 31799598 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(5):1005-1025

PubMed: 30599067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

Br J Cancer, 2019, 121(12):1039-1049

PubMed: 31690832 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 10:409

PubMed: 30915074 ( click the link to review the publication )

Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

J Mol Med (Berl), 2019, 97(7):957-972

PubMed: 31025088 ( click the link to review the publication )

J Immunol, 2019, 203(12):3199-3208

PubMed: 31732526 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786

PubMed: 31694931 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31380285 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Stem Cells Int, 2019, 2019:8451282

PubMed: 30992706 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2019, 22(4):317-328

PubMed: 30668714 ( click the link to review the publication )
Endocrinology, 2019, 160(11):2600-2617

PubMed: 31322702 ( click the link to review the publication )

Skelet Muscle, 2019, 9(1):12

PubMed: 31113472 ( click the link to review the publication )

Biomed Pharmacother, 2019, 115:108570

PubMed: 31054509 ( click the link to review the publication )

Life Sci, 2019, 10.1016/j.lfs.2019.116583

PubMed: 31226417 ( click the link to review the publication )

Cancer Biol Ther, 2019, 20(5):700-710

PubMed: 30571927 ( click the link to review the publication )

Dev Biol, 2019, 449(2):122-131

PubMed: 30826398 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):669-682

PubMed: 30849634 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(3):e0213186

PubMed: 30830950 ( click the link to review the publication )

Pain Res Manag, 2019, 2019:1648919

PubMed: 30809320 ( click the link to review the publication )

Oncotarget, 2019, 10(20):1903-1917

PubMed: 30956773 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 10.1016/j.jcmgh.2019.10.005

PubMed: 31654770 ( click the link to review the publication )

eNeuro, 2019, 6(1)

PubMed: 30783618 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )

Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

EMBO Rep, 2018, 19(9)

PubMed: 30021835 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Neuropsychopharmacology, 2018, 43(8):1779-1788

PubMed: 29760409 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):623

PubMed: 29795376 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1081

PubMed: 30349042 ( click the link to review the publication )

Arch Toxicol, 2018, 92(7):2227-2243

PubMed: 29845424 ( click the link to review the publication )

Basic Res Cardiol, 2018, 114(1):3

PubMed: 30446837 ( click the link to review the publication )

Oncoimmunology, 2018, 7(11):e1466018

PubMed: 30377559 ( click the link to review the publication )
Mol Cancer Ther, 2018, 17(9):2013-2023

PubMed: 29934340 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2013-2023

PubMed: 29934340 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2018, 1864(8):2610-2622

PubMed: 29684588 ( click the link to review the publication )

Oncogenesis, 2018, 7(4):36

PubMed: 29691367 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(11)

PubMed: 30424007 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

Sci Rep, 2018, 8(1):8492

PubMed: 29855565 ( click the link to review the publication )

Sci Rep, 2018, 8(1):12886

PubMed: 30150730 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13638

PubMed: 30206377 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9391

PubMed: 29925922 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

Sci Rep, 2018, 8(1):12886

PubMed: 30150730 ( click the link to review the publication )

Mol Pharmacol, 2018, 94(2):793-801

PubMed: 29880639 ( click the link to review the publication )

Biochem J, 2018, 475(24):3921-3932

PubMed: 30552170 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(1):65-75

PubMed: 29721849 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207915

PubMed: 30481203 ( click the link to review the publication )

PLoS One, 2018, 13(3):e0194661

PubMed: 29579087 ( click the link to review the publication )

J Med Virol, 2018, 90(9):1478-1485

PubMed: 29704439 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2620-2630

PubMed: 29704392 ( click the link to review the publication )

Oncol Lett, 2018, 16(2):1967-1974

PubMed: 30008890 ( click the link to review the publication )
JCI Insight, 2018, 3(4)

PubMed: 29467324 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36413-36429

PubMed: 30559927 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Oncotarget, 2018, 9(39):25630-25646

PubMed: 29876013 ( click the link to review the publication )

Cond Med, 2018, 1(2):64-72

PubMed: 30135960 ( click the link to review the publication )

Oncotarget, 2018, 9(28):19597-19612

PubMed: 29731968 ( click the link to review the publication )

Oncotarget, 2018, 9(63):32182-32190

PubMed: 30181808 ( click the link to review the publication )

Data Brief, 2018, 17:1314-1319

PubMed: 29876485 ( click the link to review the publication )

Korean J Physiol Pharmacol, 2018, 22(1):23-33

PubMed: 29302209 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

J Clin Invest, 2017, 127(6):2235-2248

PubMed: 28436940 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(11):6334-6349

PubMed: 28369619 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(51):E10981-E10990

PubMed: 29203668 ( click the link to review the publication )

Cell Rep, 2017, 19(4):875-889

PubMed: 28445736 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(21):3865-3880

PubMed: 28832971 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(21):3865-3880

PubMed: 28832971 ( click the link to review the publication )

J Med Chem, 2017, 60(13):5334-5348

PubMed: 28581289 ( click the link to review the publication )

Plant Physiol, 2017, 175(4):1760-1773

PubMed: 29018096 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(7):858-869

PubMed: 28669525 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Discov, 2017, 7(8):852-867

PubMed: 28408401 ( click the link to review the publication )
Front Immunol, 2017, 8:671

PubMed: 28659914 ( click the link to review the publication )

Cancer Discov, 2017, 7(8):852-867

PubMed: 28408401 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(12):2689-2700

PubMed: 28802253 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2017, 6:54-65

PubMed: 28664166 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

J Virol, 2017, 91(16)

PubMed: 28566376 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10921

PubMed: 28883618 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12084

PubMed: 28935977 ( click the link to review the publication )

Sci Rep, 2017, 7(1):8641

PubMed: 28819194 ( click the link to review the publication )

Mech Ageing Dev, 2017, 166:6-15

PubMed: 28843433 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 361(1):140-150

PubMed: 28174211 ( click the link to review the publication )

J Neuropathol Exp Neurol, 2017, 76(12):1000-1007

PubMed: 29136455 ( click the link to review the publication )

J Endocrinol, 2017, 233(3):369-379

PubMed: 28438776 ( click the link to review the publication )

Am J Physiol Renal Physiol, 2017, 312(3):F502-F515

PubMed: 28052874 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Int J Mol Med, 2017, 40(3):661-672

PubMed: 28677722 ( click the link to review the publication )

Bioorg Med Chem, 2017, 25(7):2105-2132

PubMed: 28259528 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:3-10

PubMed: 27761809 ( click the link to review the publication )

Oncotarget, 2017, 8(69):114156-114172

PubMed: 29371976 ( click the link to review the publication )
Oncotarget, 2017, 8(55):93825-93838

PubMed: 29212192 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3172-3187

PubMed: 29423038 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83155-83170

PubMed: 29137331 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4079-4095

PubMed: 27863422 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:375-385

PubMed: 27761836 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3172-3187

PubMed: 29423038 ( click the link to review the publication )

Sci Rep, 2017, 589:97-106

PubMed: 28273598 ( click the link to review the publication )

Nat Microbiol, 2016, 1:16174

PubMed: 27694949 ( click the link to review the publication )

Kidney Int, 2016, 89(2):317-26

PubMed: 26509586 ( click the link to review the publication )

Kidney Int, 2016, 89(2):317-26

PubMed: 26509586 ( click the link to review the publication )

Cancer Res, 2016, 76(10):3067-77

PubMed: 26980768 ( click the link to review the publication )

Cell Death Differ, 2016, 23(8):1312-21

PubMed: 26915294 ( click the link to review the publication )

Sci Signal, 2016, 9(422):ra34

PubMed: 27048565 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:76

PubMed: 27437033 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:62

PubMed: 27231489 ( click the link to review the publication )

Oncoimmunology, 2016, 5(11):e1219008

PubMed: 27999738 ( click the link to review the publication )

Oncoimmunology, 2016, 5(6):e1164919

PubMed: 27471639 ( click the link to review the publication )

Osteoarthritis Cartilage, 2016, 24(8):1451-60

PubMed: 27072078 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(2):299-312

PubMed: 26772204 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2432-2441

PubMed: 27474150 ( click the link to review the publication )

Pharmacol Res, 2016, 103:328-39

PubMed: 26657418 ( click the link to review the publication )
Transl Psychiatry, 2016, 6(12):e974

PubMed: 27922638 ( click the link to review the publication )

Dis Model Mech, 2016, 9(5):541-52

PubMed: 26989193 ( click the link to review the publication )

J Virol, 2016, 90(20):9018-28

PubMed: 27466424 ( click the link to review the publication )

Front Cell Neurosci, 2016, 10:221

PubMed: 27729849 ( click the link to review the publication )

Front Cell Neurosci, 2016, 9:510

PubMed: 26793062 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2016, 311(1):L124-34

PubMed: 27233998 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2016, 10.1093/ijnp/pyw035

PubMed: 27207921 ( click the link to review the publication )

Mol Brain, 2016, 9(1):79

PubMed: 27535553 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):546-57

PubMed: 27029345 ( click the link to review the publication )

BMC Cancer, 2016, 10.1186/s12885-016-2353-7

PubMed: 27188282 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Biol Chem, 2016, 397(1):75-83

PubMed: 26431101 ( click the link to review the publication )

Methods Enzymol, 2016, 573:161-81

PubMed: 27372753 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep28025

PubMed: 27320682 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71696-71702

PubMed: 27765934 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7390-402

PubMed: 26862729 ( click the link to review the publication )

Gene Regul Syst Bio, 2016, 10:9-13

PubMed: 26823649 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms7537

PubMed: ( click the link to review the publication )

Nat Commun, 2015, 6:7023

PubMed: 25960197 ( click the link to review the publication )

Nat Commun, 2015, 6:6537

PubMed: 26055519 ( click the link to review the publication )

Nat Commun, 2015, 6:6537

PubMed: 26055519 ( click the link to review the publication )
Nat Commun, 2015, 6:7023

PubMed: 25960197 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(14):3230-3240

PubMed: 25813020 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Control Release, 2015, 204:20-9

PubMed: 25681050 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 26701908 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Am J Transplant, 2015, 10.1111/ajt.13106

PubMed: 25708614 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

J Neurosci, 2015, 35(3):1250-9

PubMed: 25609639 ( click the link to review the publication )

Br J Cancer, 2015, 112(2):329-37

PubMed: 25514379 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: 25284154 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Toxicol Sci, 2015, 148(1):220-8

PubMed: 26251326 ( click the link to review the publication )

Toxicol Sci, 2015, 148(1):220-8

PubMed: 26251326 ( click the link to review the publication )

Sci Rep, 2015, 5:16873

PubMed: 26585834 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2015, 10.1093/ijnp/pyv029

PubMed: 25762717 ( click the link to review the publication )

Front Neurosci, 2015, 9:319

PubMed: 26441495 ( click the link to review the publication )

Breast Cancer Res Treat, 2015, 151(2):281-94

PubMed: 25904215 ( click the link to review the publication )
Virology, 2015, 485:340-54

PubMed: 26331681 ( click the link to review the publication )

J Appl Physiol (1985), 2015, 119(4):342-51

PubMed: 26112243 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144660

PubMed: 26713848 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0137699

PubMed: 26361334 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Future Virol, 2015, 10(4), 351–356

PubMed: ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(12):1375-85

PubMed: 26297712 ( click the link to review the publication )

Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25784-800

PubMed: 26329759 ( click the link to review the publication )

Sheng Li Xue Bao, 2015, 67(5):447-54

PubMed: 26490061 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25801-14

PubMed: 26317649 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Genes Dev, 2014, 28(14):1578-91

PubMed: 25030697 ( click the link to review the publication )

Genes Dev, 2014, 28(14):1578-91

PubMed: 25030697 ( click the link to review the publication )

PLoS Biol, 2014, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28924

PubMed: 24771510 ( click the link to review the publication )

Addict Biol, 2014, 10.1111/adb.12161.

PubMed: 25041570 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(1):32-7

PubMed: 24165483 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 7):1441-53

PubMed: 24463822 ( click the link to review the publication )

Eur J Immunol, 2014, 44(8):2478-88

PubMed: 24810486 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(3):415-27

PubMed: 24248598 ( click the link to review the publication )

Retrovirology, 2014, 11:67

PubMed: 25116364 ( click the link to review the publication )
Neuromolecular Med, 2014, 16(4):727-41

PubMed: 25063076 ( click the link to review the publication )

Pharmacological Reports, 2014, 49–55

PubMed: ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106784

PubMed: 25198282 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115401

PubMed: 25521755 ( click the link to review the publication )

Pharmacol Rep, 2014, 66(1):49-55

PubMed: 24905306 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 445(2):320-6

PubMed: 24530917 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4516-28

PubMed: 24980831 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(28):E2621-8

PubMed: 23788661 ( click the link to review the publication )

Genet Mol Biol, 2013, 36(3):299-307

PubMed: 24130434 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(1):118-27

PubMed: 23091117 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2076-86

PubMed: 23047626 ( click the link to review the publication )

J Neuroscience, 2013, 33(50):19664-76

PubMed: 24336730 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Stem Cells, 2013, 31(7):1434-45

PubMed: 23592435 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(10):2078-87

PubMed: 23939379 ( click the link to review the publication )
AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Neurochem, 2013, 129(3):509-15

PubMed: 24147654 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Infect Immun, 2013, 82(2):706-19

PubMed: 24478085 ( click the link to review the publication )

Mol Reprod Dev, 2013, 154(9):1668-79

PubMed: 23693161 ( click the link to review the publication )

Pediatr Nephrol, 2013, 28(10):1909-21

PubMed: 23052657 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74930

PubMed: 24058639 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Exp Hematol, 2013, 41(1):113-23.e2

PubMed: 22989761 ( click the link to review the publication )

Circ Res, 2012, 110(5):739-48

PubMed: 22282194 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(12):2600-9

PubMed: 23012246 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Immunol, 2012, 189(4):1792-9

PubMed: 22786766 ( click the link to review the publication )

Eur Neuropsychopharmacol, 2012, 22(9):651-6

PubMed: 22341945 ( click the link to review the publication )

J Am Heart Assoc, 2012, 1(3):e000901

PubMed: 23130137 ( click the link to review the publication )

J Virol, 2012, 86(6):3073-87

PubMed: 22238308 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41776

PubMed: 22848598 ( click the link to review the publication )

Biochem Biophys Res Commun, 2012, 428(1):121-6

PubMed: 23063976 ( click the link to review the publication )

Biomol Ther (Seoul), 2012, 20(1):81-8

PubMed: 24116279 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

J Thorac Oncol, 2011, 6(7):1152-61

PubMed: 21597390 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(49):19629-34

PubMed: 22106282 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )
Biochem Biophys Res Commun, 2011, 414(1):25-30

PubMed: 21925145 ( click the link to review the publication )

J Biomed Biotechnol, 2011, 2011:371832

PubMed: 21151613 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Mol Pain, 2010, 6:51

PubMed: 20822541 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14335

PubMed: 21179472 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14462

PubMed: 21283510 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Targets

HDAC1 ^[2] (Cell-free assay)	HDAC3 ^[2] (Cell-free assay)
0.51 μM	1.7 μM

In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21^WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. ^[1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. ^[2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
SCC-3	Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwME[xJO69VQ>?	NWC2fWJYW0GQR1XS
ALL-PO	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYG1fFJWUUN3ME2wMlA3OzV3IN88US=>	NHTae49USU6JRWK=
697	NFjKeIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF[4S2hKSzVyPUCuNFk6PzZizszN	Mli1V2FPT0WU
NCI-H748	NI\DUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXBOXBjUUN3ME2wMlExOzN2IN88US=>	NEfCeFVUSU6JRWK=
NKM-1	NHr3V3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3Pu[2lEPTB;MD6xNFkyOiEQvF2=	M3f2dXNCVkeHUh?=
ES1	M2HNVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\ifWlEPTB;MD6xNVI2PSEQvF2=	MkiwV2FPT0WU
NCI-H1963	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXS1VYJxUUN3ME2wMlEyPTd7IN88US=>	NUTJbXJxW0GQR1XS
NCI-H1417	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjOXZNKSzVyPUCuNVI6PzRizszN	MWLTRW5ITVJ?
NEC8	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;nTmlEPTB;MD6xN\|UzPyEQvF2=	M1XsdHNCVkeHUh?=
CRO-AP2	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLmTWM2OD1yLkG2PFg6KM7:TR?=	MlfYV2FPT0WU
A3-KAW	NGK2cnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVP0Z3hjUUN3ME2wMlE4PjJ5IN88US=>	M2DQ[HNCVkeHUh?=
SF539	Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\aUWlEPTB;MD6xPVU6OyEQvF2=	NFnvUWhUSU6JRWK=
NOS-1	NX7RPHVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnXbodVUUN3ME2wMlE6PjF7IN88US=>	MkflV2FPT0WU
NTERA-S-cl-D1	NXz5NlBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nZVmlEPTB;MD6yNFEyOyEQvF2=	NWHITmxCW0GQR1XS
COR-L88	NEnHeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTwcItMUUN3ME2wMlIzQTV7IN88US=>	NEDjPZlUSU6JRWK=
EM-2	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rSd2lEPTB;MD6yOFA4QSEQvF2=	M4fJcXNCVkeHUh?=
KARPAS-45	NIfkPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfvWpExUUN3ME2wMlI4QDN\|IN88US=>	MU\TRW5ITVJ?
DSH1	NXv4ZVNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTvenN[UUN3ME2wMlI5PzB6IN88US=>	NGPOW25USU6JRWK=
HT-144	M4HaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrabo1KSzVyPUCuN\|AzPTZizszN	NYHUUYRSW0GQR1XS
ATN-1	NEnUfHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;1d2lEPTB;MD6zNFU4PiEQvF2=	MoDoV2FPT0WU
HEL	NH:wZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTtT\|FUUUN3ME2wMlMyOzR6IN88US=>	MoqzV2FPT0WU
NB12	MmGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTBwM{G3OVYh\|ryP	NUK3T4VJW0GQR1XS
LU-139	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLzTWM2OD1yLkOzOVEh\|ryP	NH\SemdUSU6JRWK=
J-RT3-T3-5	M4HTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTBwM{O3NVYh\|ryP	NIr4RmlUSU6JRWK=
MOLT-13	MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1q2O2lEPTB;MD6zN\|gyKM7:TR?=	Mn7GV2FPT0WU
SR	M1[3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zZc2lEPTB;MD6zOFI3OSEQvF2=	MYXTRW5ITVJ?
CMK	NYLRd2JMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwM{W3Nlch\|ryP	M1TPZXNCVkeHUh?=
ES8	M3HjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmewTWM2OD1yLkO2NFIzKM7:TR?=	M4LJb3NCVkeHUh?=
LB647-SCLC	M1zWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWK3TJdtUUN3ME2wMlM3PzNizszN	MYrTRW5ITVJ?
TE-8	M2rCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHKeYlKSzVyPUCuN\|Y6OzVizszN	NFu1TmVUSU6JRWK=
BV-173	NGL4OotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7CTZNKSzVyPUCuN\|cyOjFizszN	MW\TRW5ITVJ?
DEL	M{SxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwM{e0PFch\|ryP	M1TYeXNCVkeHUh?=
ARH-77	M3TDPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHpdlBKSzVyPUCuN\|gyQTNizszN	NHzv[lBUSU6JRWK=
NCCIT	M2fBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLKWpptUUN3ME2wMlM5PjR7IN88US=>	MWfTRW5ITVJ?
RPMI-8402	M4PxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37tc2lEPTB;MD6zPFcxOSEQvF2=	NGfXWnJUSU6JRWK=
MONO-MAC-6	NFXDb\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwM{i3O\|Yh\|ryP	MmW3V2FPT0WU
SK-MM-2	Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwM{m4Olgh\|ryP	NIe5[pZUSU6JRWK=
CHP-126	NFn2PZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTSTWM2OD1yLkSwNlMyKM7:TR?=	MkPPV2FPT0WU
A101D	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwNECzJO69VQ>?	MkXpV2FPT0WU
SCH	NYHqU4E5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUO1RpNkUUN3ME2wMlQxOzR{IN88US=>	NGfPV\|BUSU6JRWK=
NMC-G1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1K1UmlEPTB;MD60NFM3PyEQvF2=	NXfBfVlZW0GQR1XS
NCI-H209	MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\RTWM2OD1yLkSwOlE{KM7:TR?=	NYnlS3JnW0GQR1XS
MOLT-16	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHuTWM2OD1yLkSxNFE4KM7:TR?=	NGfMflRUSU6JRWK=
RPMI-6666	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTXTWM2OD1yLkSxNVIh\|ryP	MU\TRW5ITVJ?
OPM-2	NEm2[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwNEG1NVMh\|ryP	M4jpenNCVkeHUh?=
MRK-nu-1	M1rhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELEOXFKSzVyPUCuOFMyPTNizszN	MVvTRW5ITVJ?
BC-1	NXXnPWVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXCTWM2OD1yLkSzOFA{KM7:TR?=	M4HETXNCVkeHUh?=
MHH-NB-11	NVfscYZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkj4TWM2OD1yLkSzOFU{KM7:TR?=	M1\vUXNCVkeHUh?=
Ramos-2G6-4C10	MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TyW2lEPTB;MD60N\|g6PyEQvF2=	NUT1eZNkW0GQR1XS
LS-513	NVLJSGlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPPdo93UUN3ME2wMlQ1PTBzIN88US=>	MmTvV2FPT0WU
K5	MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfZZYNKSzVyPUCuOFcxOjVizszN	MVjTRW5ITVJ?
HOP-62	NYLITIxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwNEizOVgh\|ryP	Ml[yV2FPT0WU
NCI-H187	NGrFcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\NPFlIUUN3ME2wMlQ6OjJ5IN88US=>	MYnTRW5ITVJ?
BE-13	NGTFenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXO2R4xuUUN3ME2wMlQ6PjZzIN88US=>	NEPpO\|lUSU6JRWK=
HC-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7XNmxEUUN3ME2wMlUxPDd\|IN88US=>	MUXTRW5ITVJ?
ACN	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwNUGwNlgh\|ryP	MknaV2FPT0WU
HCC1599	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\UWWlEPTB;MD61NVU4KM7:TR?=	M{nobXNCVkeHUh?=
MV-4-11	NGfHUldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHsTWM2OD1yLkWzNFQyKM7:TR?=	NVPH[otqW0GQR1XS
LC-2-ad	Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MormTWM2OD1yLkWzOlY{KM7:TR?=	M3PiS3NCVkeHUh?=
HL-60	NITnNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGr6bolKSzVyPUCuOVQzPjFizszN	M17vZ3NCVkeHUh?=
NB17	M2rOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLQTWM2OD1yLkW0N\|gh\|ryP	MYnTRW5ITVJ?
TE-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\YTWM2OD1yLkW1N\|A3KM7:TR?=	NYrCbYxKW0GQR1XS
NCI-H524	NXK3WWozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3G0SmlEPTB;MD61OVQxOSEQvF2=	M{P6OnNCVkeHUh?=
MZ7-mel	Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjOZVNKSzVyPUCuOVYyODVizszN	NHXzOYFUSU6JRWK=
L-363	MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLad5NKSzVyPUCuOVY3PTdizszN	NEn4N4JUSU6JRWK=
BL-41	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;lb3RKSzVyPUCuOVY5QDlizszN	MWrTRW5ITVJ?
LU-134-A	MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{D5XmlEPTB;MD61O\|A4OyEQvF2=	MX3TRW5ITVJ?
SIG-M5	NUn1VJhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYCyUo9uUUN3ME2wMlU4QDR6IN88US=>	M1y3NXNCVkeHUh?=
ONS-76	Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDuWpliUUN3ME2wMlU5OjR{IN88US=>	MW\TRW5ITVJ?
KARPAS-299	NEDaWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkX5TWM2OD1yLkW4OVA1KM7:TR?=	NELjOZFUSU6JRWK=
DU-4475	NX3FT\|JET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrZco04UUN3ME2wMlU5PzB\|IN88US=>	M{DMTXNCVkeHUh?=
NB69	Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1q5R2lEPTB;MD61PVgzPSEQvF2=	M4\CTHNCVkeHUh?=
MHH-PREB-1	NH3RbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTBwNkC3NVkh\|ryP	M3;H[3NCVkeHUh?=
LU-165	M1fjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIq0PYtKSzVyPUCuOlE5OTJizszN	MluzV2FPT0WU
LOUCY	M{K4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFe4TpBKSzVyPUCuOlM{PjRizszN	Mo\TV2FPT0WU
NCI-H526	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwNkO1OFEh\|ryP	NV73OHZnW0GQR1XS
KE-37	MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TL[mlEPTB;MD62OFI4PiEQvF2=	NVXIXlY1W0GQR1XS
NALM-6	M1H6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1niZ2lEPTB;MD62OFg3KM7:TR?=	MXHTRW5ITVJ?
CW-2	NVrZVIRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\CZmlEPTB;MD62OVc6PCEQvF2=	MorJV2FPT0WU
SU-DHL-1	NHf2RppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DCfmlEPTB;MD62OVk1PyEQvF2=	NUnmVFhjW0GQR1XS
NB13	MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn[yTWM2OD1yLk[2PFE4KM7:TR?=	NXrUblA{W0GQR1XS
QIMR-WIL	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGm4dIVKSzVyPUCuOlg{PDNizszN	M3\QZnNCVkeHUh?=
ECC12	MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXH5ToxrUUN3ME2wMlcxODh4IN88US=>	NEKxelJUSU6JRWK=
KALS-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXi1VYZKUUN3ME2wMlcxPDl{IN88US=>	Ml7uV2FPT0WU
COR-L279	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;ZcWhKSzVyPUCuO\|A6QTZizszN	Ml24V2FPT0WU
NB14	MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwN{K2NVch\|ryP	MkjlV2FPT0WU
CCRF-CEM	M37y[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTBwN{S2OlEh\|ryP	MVfTRW5ITVJ?
SW954	M4e5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Xkc2lEPTB;MD63OVk6QSEQvF2=	NHXMRodUSU6JRWK=
IST-SL1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\ZeWFKSzVyPUCuO\|c{PDhizszN	NYW1OIIxW0GQR1XS
LAMA-84	NVjjRZkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTBwN{e1Olch\|ryP	NGqzeHZUSU6JRWK=
Daudi	NWmwZ3VxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfqXmt3UUN3ME2wMlc4PjhzIN88US=>	NUnIVFlbW0GQR1XS
BC-3	NHz0[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHxfWVYUUN3ME2wMlc5OzB6IN88US=>	NGfEdVRUSU6JRWK=
HCC2998	MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwN{izOkDPxE1?	NFftOmdUSU6JRWK=
NCI-H69	NFrtW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PyUmlEPTB;MD64NFE1PyEQvF2=	MkDNV2FPT0WU
CPC-N	Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwOEC1NlQh\|ryP	MkSxV2FPT0WU
NOMO-1	MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEH5cppKSzVyPUCuPFExQDRizszN	MY\TRW5ITVJ?
CESS	NX;FSZc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYOwVpliUUN3ME2wMlgyOTl5IN88US=>	NIG3WJZUSU6JRWK=
LC4-1	Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1:2[WlEPTB;MD64OFAxPyEQvF2=	NGW0fnpUSU6JRWK=
BL-70	NHLIVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPBTWM2OD1yLki1O\|AzKM7:TR?=	MlzDV2FPT0WU
ES4	NXPiR5VsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nq[2lEPTB;MD64OVg3QCEQvF2=	NXvYTnJlW0GQR1XS
HCE-T	NV24O\|hUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTYTWM2OD1yLki3NVcyKM7:TR?=	NHLiUGJUSU6JRWK=
JAR	MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDaS3NKSzVyPUCuPFc5OjdizszN	NI\1VoZUSU6JRWK=
ST486	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwOEe5NVch\|ryP	NHfK[llUSU6JRWK=
KS-1	NEjiVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2W5fmlEPTB;MD64PFA6PiEQvF2=	MlvWV2FPT0WU
GDM-1	NVP4UWFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwOEi2PFch\|ryP	M1PF[nNCVkeHUh?=
EHEB	NV7l[44xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\zfHhZUUN3ME2wMlkzPTh3IN88US=>	NVPwN4Z5W0GQR1XS
LB2518-MEL	M1[zNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwOUOyPFQh\|ryP	MmfMV2FPT0WU
GOTO	M4P0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDsT2dKSzVyPUCuPVUxPzZizszN	M2GwZnNCVkeHUh?=
LXF-289	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjmUIFxUUN3ME2wMlk2QTBzIN88US=>	NIDmUopUSU6JRWK=
ES6	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF6xUVNKSzVyPUCuPVY1OzdizszN	M1;mV3NCVkeHUh?=
OS-RC-2	NUeyO3dOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTBwOU[4N{DPxE1?	Ml7zV2FPT0WU
DMS-153	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTBwOUe0Olkh\|ryP	M{DNTXNCVkeHUh?=
SK-PN-DW	M3TPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTBwOUe4N\|Eh\|ryP	NVyxfG56W0GQR1XS
HH	NV\UO2JrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm[zTWM2OD1yLkm4PVU6KM7:TR?=	NHr6Z5RUSU6JRWK=
SH-4	NXPycmpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPpcVdrUUN3ME2xMlAzPDFizszN	Moe2V2FPT0WU
MOLT-4	M{HmcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTFwMEO0OVQh\|ryP	Mmm2V2FPT0WU
TGW	M1\MXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M124TGlEPTB;MT6wO\|Y4PSEQvF2=	MYDTRW5ITVJ?
L-540	M{HSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLpNmlKSzVyPUGuNVA3ODRizszN	MnPPV2FPT0WU
PF-382	Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fmXmlEPTB;MT6xNVUyOyEQvF2=	MX3TRW5ITVJ?
LC-1F	NF7abGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFWyPGhKSzVyPUGuNVIxODdizszN	Mn\qV2FPT0WU
OVCAR-4	Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nqPGlEPTB;MT6xN\|E3PSEQvF2=	Mn;BV2FPT0WU
A4-Fuk	M2KybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXK2b4p4UUN3ME2xMlE2OzZ2IN88US=>	M3rlOHNCVkeHUh?=
HCC2218	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1S0Z2lEPTB;MT6xOlY1OSEQvF2=	NVfRO5hMW0GQR1XS
HAL-01	NVLZNHc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTFwMU[5OFMh\|ryP	NHfMS2lUSU6JRWK=
IST-MEL1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPNXphKSzVyPUGuNVc3PTlizszN	MVrTRW5ITVJ?
NCI-H719	NI\oRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTFwMUe4PVgh\|ryP	NXHHXVVvW0GQR1XS
EVSA-T	NXHqWGR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTFwMUixNVQh\|ryP	M2HZRXNCVkeHUh?=
SK-NEP-1	NInsVI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rUWGlEPTB;MT6yNFI3PiEQvF2=	NFz3TFhUSU6JRWK=
OCUB-M	M1PyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TSS2lEPTB;MT6yNVQ5QSEQvF2=	NIC2[GZUSU6JRWK=
MEG-01	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoixTWM2OD1zLkKyNVE5KM7:TR?=	M2HuUnNCVkeHUh?=
no-10	NWDMb2ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo[yTWM2OD1zLkKzNVEzKM7:TR?=	MmCzV2FPT0WU
MHH-CALL-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vnU2lEPTB;MT6yOFczOSEQvF2=	NH34VWVUSU6JRWK=
SK-N-DZ	NGm4RpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHpR41KSzVyPUGuNlQ4PzZizszN	NYH0RpBKW0GQR1XS
SCLC-21H	M2r6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TUSmlEPTB;MT6yOlQ4QCEQvF2=	NWLVUVVjW0GQR1XS
CTV-1	MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITTfGhKSzVyPUGuNlc1OjVizszN	MmHTV2FPT0WU
NB1	NFrMdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjEenM5UUN3ME2xMlI4PzN{IN88US=>	NFzoPWpUSU6JRWK=
NCI-H64	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTFwMki0OlIh\|ryP	MUHTRW5ITVJ?
MDA-MB-134-VI	MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvSUndIUUN3ME2xMlI5PTd5IN88US=>	NEfoe3JUSU6JRWK=
LB2241-RCC	M17vb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHlTWM2OD1zLkK4OlY{KM7:TR?=	MY\TRW5ITVJ?
8-MG-BA	MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTFwMki4OlYh\|ryP	NEHFSpFUSU6JRWK=
LP-1	MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnIUHRKSzVyPUGuNlk6PDdizszN	NEXrWHZUSU6JRWK=
LS-411N	NUOzcodPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrJVolKSzVyPUGuN\|A6QThizszN	MlHBV2FPT0WU
CAL-148	MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTFwM{K1OFIh\|ryP	NVfjeHp3W0GQR1XS
NCI-H2171	NX3INJVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4q3dGlEPTB;MT6zOFUxOiEQvF2=	MW\TRW5ITVJ?
JiyoyeP-2003	MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXQTWM2OD1zLkO1N\|kh\|ryP	NYf4emdVW0GQR1XS
NCI-H2107	NFmyPWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTFwM{W4PFMh\|ryP	MmDvV2FPT0WU
BB30-HNC	MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4G2SmlEPTB;MT6zPFk4QCEQvF2=	MVTTRW5ITVJ?
K-562	NH;pbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LNOWlEPTB;MT6zPVIyQSEQvF2=	NEi4XI5USU6JRWK=
PSN1	M4DQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkP4TWM2OD1zLkSyNlg4KM7:TR?=	MknWV2FPT0WU
HCC2157	M{LVV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XmNWlEPTB;MT60NlY6OSEQvF2=	MXjTRW5ITVJ?
SBC-1	MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHZTWM2OD1zLkSyO\|QyKM7:TR?=	MnTOV2FPT0WU
MC116	NGjEblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTFwNEO2NVUh\|ryP	MVXTRW5ITVJ?
KARPAS-422	Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;xTWM2OD1zLkS1N\|U5KM7:TR?=	MoTGV2FPT0WU
LB996-RCC	NV:4ZlBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3DZmxKSzVyPUGuOFcyODNizszN	NGq1TpBUSU6JRWK=
MSTO-211H	NWS5XVhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHv5T3JKSzVyPUGuOFc6QDdizszN	NUjDeIdFW0GQR1XS
BT-474	MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTFwNUG3OlQh\|ryP	M2fkNnNCVkeHUh?=
A388	NX7LWXFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjGRY1KSzVyPUGuOVE6PDVizszN	NYn2Om9wW0GQR1XS
SJSA-1	NEn3dWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTFwNUKyOkDPxE1?	MXzTRW5ITVJ?
COLO-829	M3XmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrwNlFKSzVyPUGuOVM2PjRizszN	NVTTdGhKW0GQR1XS
KM-H2	MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWD1VY5PUUN3ME2xMlU3PjdizszN	MkPWV2FPT0WU
GR-ST	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTFwNU[4NkDPxE1?	MWjTRW5ITVJ?
RPMI-8866	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITUSJpKSzVyPUGuOlAyPDRizszN	MoqwV2FPT0WU
KG-1	MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTMTWM2OD1zLk[xPVAyKM7:TR?=	NX3SOIZTW0GQR1XS
NCI-H82	NXLLboJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmSwTWM2OD1zLk[zOFA3KM7:TR?=	M3vqfnNCVkeHUh?=
LB1047-RCC	MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\IV3FKSzVyPUGuOlM1PTlizszN	NIrW[3FUSU6JRWK=
KM12	M3\2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHxTYZZUUN3ME2xMlY1PyEQvF2=	MYrTRW5ITVJ?
NB5	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXRTWM2OD1zLk[1Olc4KM7:TR?=	MlXKV2FPT0WU
HDLM-2	MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;GTWM2OD1zLk[4NlgyKM7:TR?=	M3fTUXNCVkeHUh?=
KU812	NFrXbnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfNSI1KSzVyPUGuOlk3ODVizszN	NETQ[YFUSU6JRWK=
DB	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTFwN{CzOVMh\|ryP	NEjXTWtUSU6JRWK=
HD-MY-Z	M3GwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHCTWM2OD1zLke1NlM1KM7:TR?=	NWjyfm1rW0GQR1XS
KURAMOCHI	M3zoR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzMTWM2OD1zLke3NlA4KM7:TR?=	MUnTRW5ITVJ?
ETK-1	NWTG[mIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTTTWM2OD1zLke4PFc6KM7:TR?=	NYjkflVWW0GQR1XS
SK-UT-1	NWn5S\|dJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTFwN{mzPFgh\|ryP	Ml[xV2FPT0WU
HUTU-80	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmT6TWM2OD1zLke5OVA5KM7:TR?=	M2nOUXNCVkeHUh?=
ES7	M{PD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUH1eG1SUUN3ME2xMlgxOzB{IN88US=>	NEHF[olUSU6JRWK=
SW872	M1rDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHq2V29KSzVyPUGuPFE{QTVizszN	NHjaNVFUSU6JRWK=
TK10	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfhTWM2OD1zLkizNVA5KM7:TR?=	M4nU[3NCVkeHUh?=
LB831-BLC	M3Xvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\QZmRKSzVyPUGuPFM2PjNizszN	M{Xue3NCVkeHUh?=
TE-9	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1SzcGlEPTB;MT64OFQzOiEQvF2=	MV\TRW5ITVJ?
MLMA	MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfhTWM2OD1zLki4NlM1KM7:TR?=	M2D4XHNCVkeHUh?=
D-542MG	MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmq1TWM2OD1zLki5N\|c{KM7:TR?=	NEfPcFVUSU6JRWK=
EW-16	MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HOUWlEPTB;MT65NlczKM7:TR?=	MmDlV2FPT0WU
LOXIMVI	MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7TTWM2OD1zLkmzNlgh\|ryP	M3fBXnNCVkeHUh?=
GB-1	NHzJc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;6b3VKSzVyPUGuPVM5PjZizszN	MoLxV2FPT0WU
IST-SL2	MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXq1eoR4UUN3ME2yMlAxOjZ{IN88US=>	NH3nR29USU6JRWK=
LAN-6	M4PJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTJwMEG5OlYh\|ryP	NEfZ[mJUSU6JRWK=
NCI-H510A	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTCR4l1UUN3ME2yMlA1PTB{IN88US=>	NH7y[\|RUSU6JRWK=
NCI-H1092	M3n4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fX[WlEPTB;Mj6wOVEzPCEQvF2=	MkHrV2FPT0WU
HT	M33kdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTJwMUC0OVQh\|ryP	NX\ESIhJW0GQR1XS
RL95-2	NG\ifXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vJ[2lEPTB;Mj6xNVQ5OiEQvF2=	MYfTRW5ITVJ?
NCI-H1355	MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTKdG1{UUN3ME2yMlEyPzl{IN88US=>	M{fJ[HNCVkeHUh?=
NCI-H720	M4ThZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLzTWM2OD1{LkG2PFc{KM7:TR?=	NXy3VHRzW0GQR1XS
NCI-H1522	NHnqfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7LVYN6UUN3ME2yMlIyPzJ\|IN88US=>	M1LnbnNCVkeHUh?=
LB373-MEL-D	NHuz[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfuVIRKSzVyPUKuNlY6ODJizszN	NHzNdmhUSU6JRWK=
DG-75	NIDzeHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LkOmlEPTB;Mj6yO\|E1QCEQvF2=	MVHTRW5ITVJ?
ML-2	NGLWRnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvsWWNZUUN3ME2yMlMzQDV3IN88US=>	MmntV2FPT0WU
SF126	M{LrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLKOHZjUUN3ME2yMlM{ODl2IN88US=>	MnzaV2FPT0WU
MPP-89	NWfO[\|kzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTVTWM2OD1{LkOzNVQ2KM7:TR?=	M3TrPXNCVkeHUh?=
NCI-H345	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPKTWM2OD1{LkOzNlc4KM7:TR?=	NXi2cnVOW0GQR1XS
LS-123	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HofWlEPTB;Mj6zOFk{PiEQvF2=	MmL1V2FPT0WU
NB10	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTJwNEGwPVIh\|ryP	NWrCclRxW0GQR1XS
CGTH-W-1	NYPEW3dlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn:5TWM2OD1{LkSyNlY4KM7:TR?=	NUXkTHE5W0GQR1XS
CP66-MEL	NXjlSmFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3r5dmlEPTB;Mj60O\|c4KM7:TR?=	NEjTU\|dUSU6JRWK=
L-428	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLZTWM2OD1{LkS4OVIyKM7:TR?=	M2flRXNCVkeHUh?=
DMS-79	MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTJwNUSxNFMh\|ryP	MWTTRW5ITVJ?
NCI-H1882	NGjXdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorCTWM2OD1{Lk[3OVYzKM7:TR?=	MorJV2FPT0WU
KGN	NHroSZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFf6SZJKSzVyPUKuO\|Y5PzZizszN	M{fYfnNCVkeHUh?=
EW-1	NVXteYIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTJwN{ewPFMh\|ryP	MmfSV2FPT0WU
U-266	M1XsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLLb5JKSzVyPUKuPFQ5OjNizszN	NF3PPZJUSU6JRWK=
COLO-320-HSR	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LJd2lEPTB;Mj64OVY1OSEQvF2=	MlTjV2FPT0WU
KMOE-2	M4P4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTJwOEe3NVEh\|ryP	MVvTRW5ITVJ?
BB49-HNC	MoPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXr[ZVlUUN3ME2yMlkzPDhizszN	NUPKSYw4W0GQR1XS
GI-1	NEfaN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV[2PINUUUN3ME2yMlkzQTV5IN88US=>	MVLTRW5ITVJ?
NCI-H1304	M{T3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\2TWM2OD1\|LkCwOVEyKM7:TR?=	M{DoV3NCVkeHUh?=
NCI-H2227	NXnGPWl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPFTWM2OD1\|LkCyNFc6KM7:TR?=	NF32RWRUSU6JRWK=
U-87-MG	M2m4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTNwMEO1NVMh\|ryP	M4LEbHNCVkeHUh?=
NCI-H747	NEW0XoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPVTWM2OD1\|LkC1NlA3KM7:TR?=	Mm\NV2FPT0WU
CTB-1	MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjqTWM2OD1\|LkC1N\|c3KM7:TR?=	MlvTV2FPT0WU
RPMI-8226	NESyUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjFfWFoUUN3ME2zMlE1Ozd6IN88US=>	Mnn3V2FPT0WU
NCI-H2141	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTNwMU[1OlYh\|ryP	M{TvR3NCVkeHUh?=
IST-MES1	NHnkWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTNwMUiyO\|kh\|ryP	M1;B[nNCVkeHUh?=
TE-5	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvXcHZwUUN3ME2zMlIyOzR{IN88US=>	NHrMemdUSU6JRWK=
UACC-257	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLsW2RRUUN3ME2zMlQ{PjV7IN88US=>	MWDTRW5ITVJ?
SK-N-FI	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTNwNEWyNlch\|ryP	MWTTRW5ITVJ?
MFH-ino	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXMTWM2OD1\|LkS2OVg6KM7:TR?=	NUDZUYRuW0GQR1XS
SF268	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXDTWM2OD1\|LkS4NVc1KM7:TR?=	NXjmcldqW0GQR1XS
TE-12	NGnLdphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XM[GlEPTB;Mz61NVY6QSEQvF2=	MnvSV2FPT0WU
NB6	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLHfWM6UUN3ME2zMlU2PTZ\|IN88US=>	Mkn2V2FPT0WU
DJM-1	MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHJTWM2OD1\|LkW5PFk6KM7:TR?=	NYr4[Y1OW0GQR1XS
MZ1-PC	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTNwNkG2NlQh\|ryP	M3fCRXNCVkeHUh?=
OCI-AML2	NXHHSZVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLaTmhKSzVyPUOuOlI3PzFizszN	MXjTRW5ITVJ?
NCI-H1155	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfzTWM2OD1\|LkewPVQ4KM7:TR?=	MUPTRW5ITVJ?
RKO	NYXDeFRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULneGxTUUN3ME2zMlc4OTh7IN88US=>	NXXNVnRDW0GQR1XS
ECC4	NI\ZeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTNwOUexPVUh\|ryP	M3L1O3NCVkeHUh?=
BB65-RCC	NXfBcFI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXhXmtKSzVyPUOuPVc2PDdizszN	M{TvR3NCVkeHUh?=
EB-3	NFXtVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3lUVFsUUN3ME2zMlk6PjN\|IN88US=>	M4mwd3NCVkeHUh?=
SHP-77	NHHhUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTRwMEC1NlQh\|ryP	NUfob\|lQW0GQR1XS
NCI-H2196	NELEW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXXcYFKSzVyPUSuNFU3OjVizszN	MXPTRW5ITVJ?
GI-ME-N	NFfZO\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTXTWM2OD12LkC2N\|k6KM7:TR?=	NXyxNGFbW0GQR1XS
MN-60	NE\PXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PwZmlEPTB;ND6xNFg4KM7:TR?=	MX3TRW5ITVJ?
NCI-H1694	M1:5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPJVXlKSzVyPUSuNVM1ODVizszN	Ml3wV2FPT0WU
LU-65	M4fXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjvOnRKSzVyPUSuNVU{OzJizszN	M3[zbXNCVkeHUh?=
NCI-H1436	NFrqWopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3uTWM2OD12LkG4N\|M{KM7:TR?=	M2nwSHNCVkeHUh?=
KINGS-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7hfHZnUUN3ME20MlMyPDN{IN88US=>	MlTsV2FPT0WU
GT3TKB	NGS4SFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPJU4FnUUN3ME20MlM{OjZ6IN88US=>	MVTTRW5ITVJ?
Becker	MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXsOJRKSzVyPUSuN\|c{OTJizszN	NIjhXIxUSU6JRWK=
HCC1187	MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjNe2lKSzVyPUSuPFk3PTdizszN	MXHTRW5ITVJ?
D-502MG	M3m4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DRVGlEPTB;NT6wNFQyPiEQvF2=	M2HlPHNCVkeHUh?=
VA-ES-BJ	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LCVGlEPTB;NT6xN\|c4QCEQvF2=	NVn5fZdpW0GQR1XS
NB7	NEHDOYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIK4TlRKSzVyPUWuNVQyOTJizszN	MmGxV2FPT0WU
SW962	NV3IXGFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTVwM{i4NVQh\|ryP	NX65NnUzW0GQR1XS
no-11	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVezPHpIUUN3ME21Mlc3OzR\|IN88US=>	NXjpTnExW0GQR1XS
KNS-81-FD	NUe4TJllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTVwOUC2PVQh\|ryP	NILzb3dUSU6JRWK=
COLO-684	MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zQ[GlEPTB;NT65PVQ6PCEQvF2=	NFTPPXRUSU6JRWK=
D-263MG	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTZwMEi4PVUh\|ryP	NGfYXZVUSU6JRWK=
EW-24	NGDYUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX33enFUUUN3ME22MlI5PTFizszN	NYTQfZFSW0GQR1XS
TE-10	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDWcXJKSzVyPU[uOFI3OjNizszN	MXjTRW5ITVJ?
EKVX	M{\XOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\pOWlEPTB;Nj60OlMzOSEQvF2=	MXrTRW5ITVJ?
NCI-H1648	NH[3UW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXKZ4NKSzVyPU[uOlc2PTdizszN	M1vOZ3NCVkeHUh?=
LB771-HNC	NHvPT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jGd2lEPTB;Nj65NlMxOSEQvF2=	M2mxS3NCVkeHUh?=
SK-MEL-1	NEHTUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M16w[2lEPTB;OD6xN\|E3PiEQvF2=	NVzGR2FMW0GQR1XS
COLO-668	M1PreWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\lR2lEPTB;OD6yO\|c5PiEQvF2=	M3XreXNCVkeHUh?=
EW-12	NECx[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRThwNEC4NFMh\|ryP	MWHTRW5ITVJ?
A253	NYDQcmZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TUOmlEPTB;OD64OFY3OSEQvF2=	NUDBcZZ{W0GQR1XS
NCI-H2126	MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHlV493UUN3ME24Mlg6OzF7IN88US=>	M4W2S3NCVkeHUh?=
Calu-6	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRThwOUmwOFIh\|ryP	MoLBV2FPT0WU
NCI-H23	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrlWGxNUUN3ME25MlE4PzR4IN88US=>	NWixNol2W0GQR1XS
WSU-NHL	NX:zO4YzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlj4TWM2OD17Lke3OFc5KM7:TR?=	MnrtV2FPT0WU
MMAC-SF	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkiyTWM2OD17Lkm3PVA1KM7:TR?=	NXjTOVdLW0GQR1XS
SK-LMS-1	NF7RXI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTFyLkK4N\|Qh\|ryP	MVrTRW5ITVJ?
GCIY	NH3Yb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfNTII1UUN3ME2xNE42QTJ2IN88US=>	NVnIPWtYW0GQR1XS
TE-15	MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzuTodQUUN3ME2xNU43ODB2IN88US=>	MYTTRW5ITVJ?
EoL-1-cell	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE[wR4hKSzVyPUGxMlc3QDJizszN	MX\TRW5ITVJ?
NCI-H2081	M4D5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTFzLke3PFYh\|ryP	NXjJeHF2W0GQR1XS
EW-3	M3TBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rJSmlEPTB;MUKuNlQ3OyEQvF2=	MVHTRW5ITVJ?
CAS-1	NGHVT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LRbmlEPTB;MUKuN\|Y{OSEQvF2=	NWC2dIx4W0GQR1XS
C2BBe1	NVv5UFQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHZbW1KSzVyPUGyMlYyOzFizszN	Mm\UV2FPT0WU
D-247MG	NVfR[XhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTF{Lke5OVIh\|ryP	NFHXVYRUSU6JRWK=
NCI-SNU-5	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEK0ZlBKSzVyPUGyMlgxOTNizszN	NFXHPHdUSU6JRWK=
LS-1034	NFLtVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrtTWM2OD1zND6zPVc2KM7:TR?=	NV\zUFBLW0GQR1XS
EW-18	M{XUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofETWM2OD1zND60OFgh\|ryP	NEf1[GlUSU6JRWK=
Raji	MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjXTWM2OD1zND61NFQ6KM7:TR?=	NEjmSFNUSU6JRWK=
D-283MED	MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHwTWM2OD1zND62NlcyKM7:TR?=	MU\TRW5ITVJ?
MZ2-MEL	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHO5d3pKSzVyPUG0Mlk3QTZizszN	M3XibnNCVkeHUh?=
NCI-SNU-16	MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETnWIVKSzVyPUG1MlQ3OzNizszN	NIHCVFVUSU6JRWK=
P30-OHK	NEfHT\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTF5Lke4N\|Eh\|ryP	MXLTRW5ITVJ?
RXF393	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTF7LkCxPFYh\|ryP	Mkm4V2FPT0WU
NCI-H1395	NITH[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fzWmlEPTB;MkCuOlcxOyEQvF2=	MXnTRW5ITVJ?
U-698-M	MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;1TWM2OD1{MD63NFc2KM7:TR?=	MXLTRW5ITVJ?
NCI-SNU-1	NEDjVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPQVVVXUUN3ME2yNE44OjJ\|IN88US=>	MmTpV2FPT0WU
SW684	Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljkTWM2OD1{MT6xO\|E3KM7:TR?=	MYPTRW5ITVJ?
NCI-H716	NWDEbFY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1H4UGlEPTB;MkGuN\|E2PCEQvF2=	NV3Ue2E3W0GQR1XS
JVM-2	NF7BdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXFTWM2OD1{MT60NVM{KM7:TR?=	M3TjTXNCVkeHUh?=
NCI-H1581	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXHTWM2OD1{Mj60NVQ5KM7:TR?=	NInpfIJUSU6JRWK=
CA46	NInRdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXPXIhKSzVyPUOxMlY6OzZizszN	NUfPemhjW0GQR1XS
SNB75	MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DOXmlEPTB;M{OuOlUxOyEQvF2=	NUfTXVM1W0GQR1XS
KNS-42	MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTN3Lkm2NlQh\|ryP	MmjtV2FPT0WU
TUR	NES5bY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;hcXZKSzVyPUO2MlA2OjFizszN	MnnkV2FPT0WU
REH	MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTN5LkiyNVEh\|ryP	M4Pa[nNCVkeHUh?=
EW-22	M4fBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIewT5VKSzVyPUSyMlI5QDVizszN	MmnXV2FPT0WU
NCI-H446	M2DlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTR{Lke4OVMh\|ryP	MUfTRW5ITVJ?
ES3	NHi3O2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVKwWlg3UUN3ME20N{4yOzN7IN88US=>	M12wPXNCVkeHUh?=
EW-11	M3zyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7PVHhKSzVyPUS0MlgzOThizszN	NGPlXVlUSU6JRWK=
RH-1	NIf6T2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFezdJRKSzVyPUS3MlU5OTJizszN	MlvmV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; PubMed: 24203492 Pharm Res HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. Cleaved PARP; PubMed: 19148581 J Neurooncol Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control. Caspase 8 ; PubMed: 19148581 J Neurooncol Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression. DR4 / DR5; PubMed: 19148581 J Neurooncol Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h. TopoIIα / TopoIIβ; PubMed: 21254166 Hepatology Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.	24203492 19148581 21254166
Immunofluorescence	phalloidin / snail; PubMed: 29855565 Sci Rep (C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed. DR4 / DR5; PubMed: 19148581 J Neurooncol Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls. H3K4Me3 / H3K9Me3; PubMed: 22468166 Mol Cell Pharmacol Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.	29855565 19148581 22468166
Growth inhibition assay	Cell proliferation; PubMed: 24203492 Pharm Res (A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. , P < 0.05, ; P ≤ 0.01; **, P ≤ 0.001 Cell viability; PubMed: 28969017 Oncotarget PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.	24203492 28969017
ELISA	GCP-2 / MCP-2 / MIF ; PubMed: 24241152 Molecules MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).	24241152

In vivo

MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. ^[1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. ^[4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. ^[5]

Protocol

Kinase Assay: ^[6]	- Collapse Standard HDAC Assays: Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λ_ex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. K_m and V_max values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research: ^[2]	- Collapse Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells Concentrations: ~ 10 μM Incubation Time: 3 days Method: Cancer cells (5 × 10³) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO₂-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na₂HPO₄ is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice. Dosages: 12.3, 24.5 and 49 mg/kg Administration: Administered orally once daily 5 days per week for 4 weeks (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	75 mg/mL (199.25 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Entinostat (MS-275) SDF

Molecular Weight	376.41
Formula	C₂₁H₂₀N₄O₃
CAS No.	209783-80-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SNDX-275
Smiles	NC1=CC=CC=C1NC(=O)C2=CC=C(CNC(=O)OCC3=CN=CC=C3)C=C2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03829930	Recruiting	Drug: Entinostat\|Drug: Enzalutamide	Prostate Adenocarcinoma	George Washington University	May 1 2019	Phase 1
NCT03765229	Recruiting	Drug: Entinostat\|Drug: Pembrolizumab	Melanoma	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals Inc.	March 22 2019	Phase 2
NCT03473639	Recruiting	Drug: Entinostat\|Drug: Capecitabine	Metastatic Breast Cancer\|Breast Cancer	University of Virginia\|Syndax Pharmaceuticals	January 29 2019	Phase 1
NCT03361800	Active not recruiting	Drug: Entinostat	Breast Cancer\|Invasive Breast Cancer\|ER-Negative PR-Negative HER2-Negative Breast Cancer	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals\|National Cancer Institute (NCI)	November 28 2018	Early Phase 1
NCT03192111	Completed	Drug: Entinostat	Renal Impairment\|Healthy Volunteer	Syndax Pharmaceuticals	July 27 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to use Entinostat（Catalog No.S1053） for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?
Answer:
2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Entinostat (MS-275)